Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models

Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models

Three-dimensional (3D) cancer models are revolutionising research, allowing for the recapitulation of an in vivo-like response through the use of an in vitro system, which is more complex and physiologically relevant than traditional monolayer cultures. Cancers such as ovarian (OvCa) are prone to de...

Full description

Bibliographic Details
Main Authors:	Rachel Kerslake, Birhanu Belay, Suzana Panfilov, Marcia Hall, Ioannis Kyrou, Harpal S. Randeva, Jari Hyttinen, Emmanouil Karteris, Cristina Sisu
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Cancers
Subjects:	ovarian cancer high-grade serous ovarian cancer (HGSOC) monolayer 2D 3D scaffold
Online Access:	https://www.mdpi.com/2072-6694/15/13/3350

Similar Items

Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer
by: Rachel Kerslake, et al.
Published: (2022-12-01)

Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer
by: Rachel Kerslake, et al.
Published: (2022-10-01)

Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro
by: Yilin Dai, et al.
Published: (2024-01-01)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
by: Marcus Vetter, et al.
Published: (2022-11-01)

Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary
by: Aeman Zahra, et al.
Published: (2022-05-01)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
by: Lu Zhang, et al.
Published: (2021-11-01)

Cell Origins of High-Grade Serous Ovarian Cancer
by: Jaeyeon Kim, et al.
Published: (2018-11-01)

Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
by: Zena Alizzi, et al.
Published: (2023-06-01)

CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
by: Katrin Kleinmanns, et al.
Published: (2020-06-01)

Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer
by: Yichao Li, et al.
Published: (2021-07-01)

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells
by: Elena Tassi, et al.
Published: (2023-10-01)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
by: Du-Bois Asante, et al.
Published: (2021-12-01)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
by: Victoria Heredia-Soto, et al.
Published: (2022-03-01)

ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian Cancer
by: Qipeng Fan, et al.
Published: (2020-12-01)

Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes
by: Chao Meng, et al.
Published: (2023-05-01)

Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer
by: Monika Raab, et al.
Published: (2024-01-01)

The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination
by: Sabrina J. Ritch, et al.
Published: (2022-04-01)

Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro
by: Alice Filipe, et al.
Published: (2022-02-01)

High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer
by: Min Li, et al.
Published: (2020-10-01)

Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study
by: Liv Cecilie Vestrheim Thomsen, et al.
Published: (2023-10-01)

Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer
by: Russell Keathley, et al.
Published: (2023-07-01)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
by: Franziska Brauneck, et al.
Published: (2023-10-01)

A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC
by: Yue Xi, et al.
Published: (2023-07-01)

Immunoexpression of p53 and p16 in Low and High-grade Serous Ovarian Cancer: A Cross-sectional Study
by: Ranajit Mandal, et al.
Published: (2023-11-01)

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints
by: Delphine Hudry, et al.
Published: (2022-10-01)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
by: Pia Roering, et al.
Published: (2022-08-01)

Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients
by: Paula Cunnea, et al.
Published: (2018-10-01)

Culture Models to Define Key Mediators of Cancer Matrix Remodeling
by: Emily Suzanne Fuller, et al.
Published: (2014-03-01)

Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer
by: Jun Jiang, et al.
Published: (2021-01-01)

Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
by: Mi Jiao, et al.
Published: (2022-09-01)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
by: Michalis Liontos, et al.
Published: (2021-03-01)

Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis
by: Natalia Iżycka, et al.
Published: (2023-08-01)

Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019-07-01)

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
by: Catherine H. Watson, et al.
Published: (2020-08-01)

Omental Macrophagic “Crown-like Structures” Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer
by: Yu-Ling Liang, et al.
Published: (2021-10-01)

Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma
by: Naoyuki Iwahashi, et al.
Published: (2021-10-01)

Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems
by: Emily Tomas, et al.
Published: (2023-04-01)

Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time
by: Michelle Bilbao, et al.
Published: (2021-11-01)

Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread
by: Núria Gendrau‐Sanclemente, et al.
Published: (2024-01-01)